"Humans and other mammals"@en . . "The reported oral LD₅₀ for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states."@en . . "Diethylpropion is rapidly absorbed from the GI tract after oral administration."@en . "A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)"@en . "Diethylpropion is rapidly absorbed from the GI tract after oral administration and is extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Diethylpropion and/or its active metabolites are believed to cross the blood-brain barrier and the placenta. Diethylpropion and its metabolites are excreted mainly by the kidney."@en . "approved"@en . . "Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany)."@en . . "Anfepramona"@en . "2-(Diethylamino)propiophenone"@en . . . . . . "Diethylpropion"@en . . . . . . . . . "# Adan RA, Vanderschuren LJ, la Fleur SE: Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. Epub 2008 Mar 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18353447 # Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19897080"@en . . . . . "Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours."@en . . . . . . . . . . . . "illicit"@en . . . . . "Take without regard to meals."@en . . " "@en . . "alpha-Benzoyltriethylamine"@en . . . . . . . . . . . . . "Diethylpropion"@en . " "@en . . . . . "1-phenyl-2-diethylamino-1-propanone"@en . . . "Amfepramone"@en . "Diethylcathinone"@en . . . . . . "Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction."@en . . . . . . . . . . . . . . . . . . . . . "Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage."@en . . "alpha-Diethylaminopropiophenone"@en . "90-84-6"@en . "(+-)-Diethylpropion"@en . "2-(Diethylamino)-1-phenyl-1-propanone"@en . "Amfepramonum"@en . "(\u00B1)-diethylpropion"@en . . . . . .